Clinical trials: Injections
Central Nervous System Pathology
Study to Find the Appropriate Dose of a New Gadolinium-based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Brain and/or Spinal Cord Conditions
Researchers in this study want to find the appropriate dose of drug BAY1747846 for adults undergoing MRI for known or highly suspected brain and/or spinal cord conditions so that the image quality is similar to that of drug…
- Trial name
- NCT04307186
- Testing
- Gadoquatrane (BAY1747846), Gadobutrol (Gadovist/Gadavist)
- Where
- 17 sites in United States, Bulgaria and 2 more
- Volunteers
- 57 people
- Sponsor
- Bayer
Temporary Correction of Wrinkles
Clinical Study to Evaluate the Correction of Wrinkles and Folds and Safety of YVOIRE Classic Versus Restylane in Nasolabial Fold Intradermal Injection
This study was purposed to evaluate the non-inferiority of HA IDF, a hyaluronic acid product, in terms of correction of wrinkles and safety in nasolabial fold intradermal injection, compared to Restylane, the control preparation.
- Trial name
- NCT03738020
- Testing
- HA IDF (YVOIRE classic), Restylane
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- LG Life Sciences
Chronic Kidney Disease, Stage 5, Secondary Hyperparathyroidism
A Study of Zemplar® Injection and Hectorol® Injection on Intestinal Absorption of Calcium in Chronic Kidney Disease
The purpose of this study is to evaluate the effects of Zemplar® Injection and Hectorol® Injection on intestinal calcium absorption in Chronic Kidney Disease Stage 5 subjects on hemodialysis.
- Trial name
- NCT00257920
- Testing
- Zemplar® injection, Hectorol® injection
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- Abbott
Alzheimer's Disease, Amnestic Mild Cognitive Impairment
Brain Uptake and Safety With Probable Alzheimer's Disease, Amnestic Mild Cognitive Impairment and Healthy Volunteers
Study to Assess Brain Uptake and Safety of AH110690 (18F) Injection in Subjects with Probable Alzheimer's Disease, Amnestic Mild Cognitive Impairment and Healthy Volunteers.
- Trial name
- ALZ201 (NCT00785759)
- Testing
- AH110690 (18F) Injection
- Where
- Norway
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- GE Healthcare
Advanced Hepatocellular Carcinoma
Clinical Study of TQB2223 Injection Combined With AK105 Injection in the Treatment of Advanced Hepatocellular Carcinoma.
TQB2223 is a recombinant, fully human antibody that binds to lymphocyte activation gene-3 (LAG-3) and blocks the LAG-3/ major histocompatibility complex class II (MHC-II) interaction, thus allowing for increased T-cell…
- Trial name
- NCT06320080
- Testing
- TQB2223 injection, Penpulimab Injection
- Where
- 3 sites in China
- Volunteers
- 22 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Chronic Lower Back Pain, Chronic Pain
Buprenorphine (CAM2038) in Subjects With a Recent History of Moderate to Severe Chronic Low Back Pain
This is a Phase III, placebo-controlled, multicenter study with an enriched-enrollment withdrawal (EEW) design to evaluate the efficacy and safety of CAM2038 in opioid-experienced subjects with moderate to severe CLBP that…
- Trial name
- CAM2038 (NCT02946073)
- Testing
- buprenorphine
- Where
- 69 sites in United States
- Volunteers
- 1,053 people
- Sponsor
- Braeburn Pharmaceuticals
Relapsing Forms of Multiple Sclerosis
Plegridy Observational Program
The primary objectives of the study are to determine the incidence of serious adverse events (SAEs) in participants with relapsing forms of multiple sclerosis (MS) in routine clinical practice and to assess the overall long-term…
- Trial name
- POP (NCT02230969)
- Testing
- peginterferon beta-1a
- Where
- 152 sites in United States, Australia and 12 more
- Volunteers
- 1,208 people
- Sponsor
- Biogen
Osteosarcoma, Other Solid Tumors
TQB2928 Injection Combined Anlotinib Hydrochloride Capsule in Recurrent/Metastatic Osteosarcoma and Other Solid Tumors
This is a multicenter, open-label, multi-cohort Phase Ib trial to evaluate the efficacy and safety of TQB2928 injection combined with anlotinib hydrochloride capsule in patients with relapsed/metastatic osteosarcoma and other…
- Trial name
- NCT06438783
- Testing
- 1200mg of TQB2928 injection+Anlotinib, 1800mg of TQB2928 injection+Anlotinib
- Where
- 5 sites in China
- Volunteers
- 20 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Spondylitis, Ankylosing
A Study of the Safety and Efficacy of Golimumab in Subjects With Active Ankylosing Spondylitis
The purpose of this study is to evaluate the safety and efficacy of subcutaneous injections (under the skin) of golimumab for the treatment of active ankylosing spondylitis [AS(arthritis of the spine)].
- Trial name
- NCT00265083
- Testing
- golimumab
- Where
- 39 sites in United States, Belgium and 7 more
- Volunteers
- 356 people
- Sponsor
- Centocor, Inc.
Solid Tumor, Lymphoma, Non-Hodgkin
A Phase Ia Clinical Study of QLF31907 Injection in Patients With Advanced Malignant Tumors
This study is designed to evaluate the safety and tolerability of QLF31907 injection, to identify the maximum tolerated dose (MTD) and dose-limiting toxicity(DLT), and determine the recommended phase Ib dose(RPIbD) and…
- Trial name
- NCT05150405
- Testing
- QLF31907
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Crohn Disease
Post-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn's Disease Patients
Post-marketing registration of Infliximab for injection in Chinese pediatric Crohn's disease patients.
- Trial name
- NCT05906576
- Testing
- Infliximab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Taizhou Mabtech Pharmaceutical Co.,Ltd
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
A Study to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group Phase II clinical trial. Its primary objective is to explore and preliminarily evaluate the efficacy and safety of LP-003 Injection in the…
- Trial name
- NCT07313917
- Testing
- LP-003 Injection
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Longbio Pharma
Recurrent/Refractory Small Cell Lung Cancer Lung Large Cell Neuroendocrine Carcinoma
SNC115 Injections in Patients With Recurrent/Refractory Small Cell Lung Cancer and Lung Large Cell Neuroendocrine Carcinoma
This study is a FIH dose escalation clinical study, with single arm, open label and design, in order to observe the preliminary safety and Pharmacokinetic of SNC115 Injection in participants with Recurrent/refractory small cell…
- Trial name
- NCT06384482
- Testing
- SNC115 injection
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Shanghai Simnova Biotechnology Co.,Ltd.
Glabellar Frown Lines
Safety Study of DWP-450 (Botulinum Purified Neurotoxin, Type A) Injection to Treat Glabellar Lines
The purpose of this study is to demonstrate the safety of multiple doses of DWP-450 (Botulinum purified neurotoxin, Type A) Injection in treatment of moderate to severe glabellar lines in adult subjects.
- Trial name
- EV-004 (NCT02184988)
- Testing
- Botulinum purified neurotoxin, Type A
- Where
- United States
- Volunteers
- 352 people, healthy volunteers welcome
- Sponsor
- Evolus, Inc.
Chronic Kidney Disease Patients
Metabolism and Excretory of HSK21542 in Maintenance Hemodialysis Patients
This is a single-center, nonrandomized, and open design study to investigate metabolism and excretion of HSK21542 in maintenance hemodialysis patients.
- Trial name
- NCT06238388
- Testing
- HSK21542 Injection
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Non Arteritic Anterior Ischemic Optic Neuropathy
Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 in Subjects With Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
This study will determine the effect of QPI-1007 on visual function in subjects with recent-onset NAION and assess the safety and tolerability of intravitreal injections of QPI-1007 in this population.
- Trial name
- NCT02341560
- Testing
- QPI-1007 Injection - 1.5 mg, QPI-1007 Injection - 3.0 mg
- Where
- 85 sites in United States, Australia and 6 more
- Volunteers
- 732 people
- Sponsor
- Quark Pharmaceuticals
Postoperative Pain Of Laparoscopic Surgery
A Trial of SHR0410 Injection for the Treatment of Pain After Laparoscopic Surgery
The study is being conducted to evaluate the efficacy and safety of SHR0410 injection for the treatment of pain after laparoscopic surgery
- Trial name
- NCT05459220
- Testing
- SHR0410 Injection
- Volunteers
- 357 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Ischemic Cardiomyopathy, Heart Failure
PET Myocardial Fatty-acid Metabolic Imaging With XTR003 Injection and 18F-FDG to Assess Myocardial Viability in Ischemic Cardiomyopathy
This is a prospective, multicenter, randomized, open-label, parallel-controlled Phase IIb study to investigate the diagnostic-prognostic utility of XTR003 Injection integrated with 18F-FDG as an exploratory clinical trial.
- Trial name
- STB-XTR-003 (NCT07443696)
- Testing
- Fasting XTR003/¹⁸F-FDG PET myocardial metabolic imaging, Glucose-loaded ¹⁸F-FDG PET Myocardial Metabolic Imaging
- Where
- 3 sites in China
- Volunteers
- 40 people
- Sponsor
- Sinotau Pharmaceutical Group
Gastrointestinal Tumors, Solid Tumor
A Study of GNC-077 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors
This study is an open-label, multicenter, dose-escalation and cohort expansion phase I clinical study to evaluate the safety, tolerability, pharmacokinetics characteristics or preliminary efficacy and antitumor activity in…
- Trial name
- NCT06755242
- Testing
- GNC-077
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Non-muscle-invasive Bladder Cancer, NMIBC
A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer
The main objectives of this study are to determine the feasibility and safety of Belzupacap Sarotalocan (AU-011, bel-sar) treatment of bladder cancer utilizing focal injections with or without laser application.
- Conditions
- Non-muscle-invasive Bladder Cancer, NMIBC, Non-Muscle Invasive Bladder Carcinoma, Non-Muscle Invasive Bladder Neoplasms
- Trial name
- NCT05483868
- Testing
- AU-011, AU-011 in Combination with Medical Laser Adminstration, AU-011 in Combination with Medical Laser Administration
- Where
- 19 sites in United States, Australia
- Volunteers
- 55 people
- Sponsor
- Aura Biosciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.